Introduction
Mucins are high molecular weight glycoproteins that are found almost exclusively on the apical surface of many glandular epithelia including the gastrointestinal, respiratory, urinary, and reproductive tracts (reviewed in Gendler, 1 Gendler and Spicer, 2 Lagow et al, 3 TaylorPapadimitriou et al 4 ) . MUC1 is a type I transmembrane glycoprotein, consisting of a very large (1000-2200 amino acids) extracellular domain comprised of a series of 20-25 amino-acid tandem repeats, a 31-amino-acid transmembrane domain, and a short (72 amino acids) cytoplasmic tail. MUC1 primarily functions in lubrication and hydration of epithelia and protection from microbial attack. However, the large extended extracellular domain of MUC1 also appears to play both adhesive and antiadhesive functions and contributes to decreased immune response. More recently, MUC1 has been implicated in signal transduction due to interactions of its highly conserved cytoplasmic tail with several signal transducing molecules [5] [6] [7] (reviewed in Gendler 1 ). Aside from its normal physiological roles, MUC1 also has been implicated in progression of numerous types of cancer including breast, colon, lung, gastric, and pancreatic cancers (reviewed in Gendler and Spicer, 2 TaylorPapadimitriou et al, 4 Ho et al 8 )
. MUC1 expression in tumors is greatly increased and accompanied by altered glycosylation and aberrant expression patterns that become more diffuse when compared to the normal apically restricted pattern. [9] [10] [11] [12] Moreover, MUC1 is proposed to help tumor cells evade host defenses by attenuating immune responses and to promote metastasis through a loss of cell-cell and cell-extracellular matrix (ECM) contact (reviewed in Taylor-Papadimitriou et al 4 ).
While the role of MUC1 in the progression and metastasis of several common cancers is well documented, the role of MUC1 in prostate cancer has received relatively little attention. There is considerable variability in MUC1 expression reported in normal prostate epithelia, from strongly positive immunoreactivity 8 to weak and/or no immunoreactivity. 8, 9, 12 In each of these cases, however, the apically restricted expression pattern is consistent with other nonneoplastic epithelia. The few studies that are available suggest that MUC1 also plays a role in progression and metastasis of prostate cancer, usually with higher immunoreactivity, altered cell-surface expression patterns (from apical expression to diffuse staining), and altered glycosylation, although there is still considerable variability among studies. 8, 9, [12] [13] [14] [15] [16] [17] Unfortunately, most of these reports are limited by small sample sizes and are confounded by differences in methodology (eg, antibodies used, processing of tissue samples) and the complexity of the disease itself.
In the current report, expression of MUC1 core protein has been evaluated in primary cultures of normal prostate epithelia and several commonly used prostate cancer cell lines under various treatment conditions. In addition, a combination of antibodies capable of detecting all forms of MUC1 independent of glycosylation state was used to examine MUC1 expression in tissue microarrays containing 278 tissue sections taken from 110 patients. MUC1 expression and subcellular distribution in tumor cells were correlated with Gleason grade. This represents the largest single study yet undertaken to examine MUC1 expression in human prostate cancer.
Materials and methods

Cell culture
Five human prostate carcinoma cell lines and primary cultures of normal prostate epithelia were used. LNCaP, PC-3, and DU-145 human prostate carcinoma cell lines (American Type Culture Collection (ATCC), Manassas, VA, USA) and C4-2 and C4-2B 4 (obtained from Dr Leland Chung, Emory University School of Medicine, Atlanta, GA, USA) were maintained in RPMI-1640 (catalog #11875; Gibco Life Technologies, Gaithersburg, MD, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) and 100 mg/ml streptomycin. Normal human prostate epithelial cells (PrEC; Clonetics, San Diego, CA, USA) were maintained in the manufacturer's recommended growth medium (Cloneticst Prostate Epithelial Cell Medium). All cultures were maintained at 371C in a humidified air: CO 2 (95 : 5; v/v) atmosphere. Cells were plated onto six-well culture plates at a density of 500 000 cells/well and maintained until approximately 90% confluent. Cells then were cultured for 24 h in phenol red-free RPMI-1640 media without FBS prior to treatment with phosphate-buffered saline (PBS; control), 100 ng/ml tumor necrosis factor alpha (TNF-a; Roche Biochemicals, Indianapolis, IN, USA), 50 ng/ml interferon gamma (IFN-g; Roche Biochemicals), 1 mM dihydrotestosterone (DHT), or combined treatments with both cytokines and DHT prepared in phenol red-free RPMI-1640 media without FBS. Combined treatment with these cytokines has synergistic effects on MUC1 expression in T47D human breast ductal carcinoma cells. 18 The concentrations used in the current report were selected based on these previous studies and other published reports and represents the highest effective concentration common to these studies. It was expected that if cytokines or DHT were stimulatory for MUC1 expression then the effect would be observed at these concentrations. DHT was dissolved in ethanol (0.1% v/v final concentration). All treatments with cytokines and DHT were for 24 h prior to sampling. 20 was analyzed concurrently as a positive control. 21 Protein was concentrated by TCA precipitation overnight at 41C. The resulting pellets were rinsed with acetone, air-dried for 10 min at room temperature, redissolved in 20 ml SEB and 20 ml Laemmli sample buffer (LSB; Biorad, Hercules, CA, USA), and heated at 951C for 2 min prior to loading.
Western blot analysis
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using a 5% (w/v) polyacrylamide stacking gel 22 and a 10% (w/v) polyacrylamide resolving gel 23 in gel running buffer (150 mM glycine, 50 mM tris-base, 0.1% (v/v) SDS, pH 8.8) under constant voltage. Proteins were transferred to a nitrocellulose membrane at 41C for 5 h at 40 V in transfer buffer (100 mM glycine, 100 mM tris-base, pH 8.3). The nitrocellulose membranes were blocked overnight at 41C with gentle rotary agitation in PBS containing 0.1% (v/v) Tween-20 (PBS-T) and 3% (w/v) bovine serum albumin (BSA). Following the blocking step, the MUC1 214D4 primary antibody (kindly provided by Dr John Hilkens of the Netherlands Cancer Institute, Amsterdam, The Netherlands), a mouse monoclonal antibody specific for a tandem repeat epitope in the extracellular domain of MUC1, 24 was added to blocking solution at a 1 : 10 000 dilution and incubated overnight at 41C with gentle rotary agitation. The blots were washed three times for 10 min each at room temperature with PBS-T. The secondary antibody, horseradish peroxidase-conjugated sheep anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA, USA), was added to blocking solution at a 1 : 200 000 dilution and incubated for 2 h at 41C with gentle rotary agitation. After three 10 min washes with PBS-T at room temperature, detection was carried out using SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford, IL, USA) and blots were exposed to X-ray film to visualize the signals.
Tissue microarray construction and sectioning MUC1 expression was assessed on microarrays containing 278 tissue sections from 110 human patients (tissue MUC1 expression in prostate tumors JC O'Connor et al specimens were obtained from Dr Mahul Amin, Director, Pathology and Laboratory Support Core, Emory University School of Medicine, Atlanta, GA, USA with permission of the Emory IRB). A total of 66 formalinfixed, paraffin-embedded radical prostatectomy specimens were selected for four different prostate tissue microarrays. Two tissue microarrays consisted of 66 primary prostate tumors and two tissue microarrays consisted of various kinds of non-neoplastic prostate specimens including normal prostate tissue and benign prostatic hyperplasia. Each array contained 100 sections, and included a section of normal lung as a positive tissue control for MUC1 expression. Tissue microarrays were constructed as follows: three tissue cores were chosen from each case with a diameter of 1 mm; a representative area of each 'donor' tissue block was punched using a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA) and brought into a recipient paraffin block. Sections (5 mm) of the resulting tissue microarray block were cut and mounted to an adhesive-coated slide system (Fisher Scientific, Pittsburgh, PA, USA).
Immunohistochemistry
The slides were deparaffinized by three 3 min washes in citrus-based clearing solvent (Stephens Scientific, Riverdale, NJ, USA) at room temperature. Sections were rehydrated in a graded ethanol series (two 2 min washes each in 100, 95, 80, and 50% ethanol) at room temperature, followed by a 5 min flowing water rinse and a 20 min rinse in PBS. Rehydrated slides were quenched by two 10 min incubations in 50 mM NH 4 Cl in PBS, and blocked for 30 min at room temperature in normal donkey serum at a final dilution of 1 : 50 in PBS. Slides then were incubated with a mouse monoclonal 214D4 primary antibody (hybridoma medium diluted 1 : 1 in PBS) for 1 h at 371C. Slides were washed three times for 5 min each at room temperature in PBS, then incubated with FITC-conjugated sheep anti-mouse antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) at a final dilution of 1 : 10 in PBS for 40 min at 371C, and washed three times for 5 min each at room temperature in PBS prior to mounting and visualization under a Zeiss Axioscope 2 fluorescent microscope equipped with a CCD camera. Exposure conditions were the same for all images taken at each magnification.
To verify the staining pattern observed with the 214D4 antibody, serial sections were stained with an affinitypurified, rabbit anti-human CT-1 MUC1 antibody specific for the cytoplasmic tail of MUC1 at a final concentration of 30 mg/ml in PBS (data not shown). MUC1 recognition by the CT-1 antibody ensured that potential differences in MUC1 glycosylation in the prostate cancer sections was not affecting the ability of the 214D4 antibody to recognize MUC1. In addition, this approach would detect forms of MUC1 lacking tandem repeat regions. 1, 15 The use of CT-1 antibody on formalinfixed paraffin-embedded tissue required antigen retrieval to optimize detection of MUC1. The antigen retrieval method detects a pattern of MUC1 expression in formalin-fixed paraffin-embedded tissue similar in intensity and distribution to that obtained on a frozen tissue (see Figure 4 for example). Therefore, in most cases, only the 214D4 patterns are presented herein since they are reflective of both antibody staining patterns. For antigen retrieval, slides were immersed in 250 ml of boiling sodium citrate buffer (0.01 M, pH 6.0) for 10 min, cooled at 41C for 20-30 min, and then rinsed three times for 5 min each at room temperature in PBS. Antigen retrieval was performed after rehydration, but prior to quenching and blocking. The subsequent staining procedure was identical to that used for the 214D4 antibody. CT-1 was detected by FITC-conjugated donkey antirabbit antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The combination of 214D4 and CT-1 antibodies was chosen to ensure that all forms of MUC1 potentially present in prostate tissues would be detected. Sections initially were scored positive or negative based on positive staining on any portion of the section. The positive staining then was scored according to its association with tumor or benign cells since both may be present within a section. The subcellular distribution of the staining pattern was determined for both positively stained tumor or benign cells as: apical only, diffuse cytoplasmic only, or apical and diffuse cytoplasmic (mixed) staining. Finally, a Gleason grade was determined for each tumor section (grading performed on serial sections stained by hematoxylin and eosin). Tumors were considered positive for MUC1 only when tumor cells displayed positive staining regardless of whether benign cells within the section were positive or negative. The threshold cutoff for positive staining was as follows: tumor tissue exhibiting only low-intensity diffuse cytoplasmic staining, barely detectable above background by 214D4 and negative by CT-1, was considered negative. If a section was missing at a position or damaged during processing in either the arrays evaluated for MUC1 staining or Gleason grade, it was not included in the final data set.
Results
Cytokine and DHT responsiveness of MUC1 in PrEC and prostate cancer cell lines Western blotting was used to determine basal MUC1 protein expression in primary cultures of normal prostate epithelial cells and several human prostate cancer cell lines (Table 1, Figure 1 ). PrEC displayed low basal MUC1 expression; however, there was considerable heterogeneity among the prostate carcinoma cell lines. LNCaP, as well as the LNCaP sublines, C4-2 and C4-2B, had no detectable expression of MUC1, even with high protein concentrations (40-mg) and long exposure times. PC-3 (5-mg protein) had significant basal MUC1 protein expression, similar to the level observed in 40-mg of PrEC cell protein. DU-145 cells had the highest basal level of MUC1 expression, equivalent to the level expressed in the positive control HES cell line.
In light of studies indicating that MUC1 expression is stimulated by steroid hormones and cytokines in other systems, 18, 25, 26 we evaluated the ability of IFN-g, TNF-a, and DHT to induce MUC1 expression in PrEC and prostate cancer cell lines. PrEC expressed moderately higher amounts of MUC1 after treatment with IFN-g or TNF-a alone; however, combined cytokine treatment produced a highly synergistic increase in MUC1 expression. DHT had no effect on MUC1 expression whether added alone or in combination with cytokines. None of the agents alone or in combination induced MUC1 expression in LNCaP, C4-2, or C4-2B cells. Since the levels of cytokines and DHT used in these studies were at the highest extreme of physiologically observed concentrations, we concluded that they had no effect on MUC1 expression in the LnCaP cell line or its derivatives. PC-3 cells showed a similar responsiveness as PrEC, although IFN-g alone had a greater affect in the PC-3 cells. DU-145 cells, with the highest basal MUC1 expression, showed no further increase in response to cytokine or DHT treatment in any combination.
Immunohistochemistry of human prostate tissue sections
Immunohistochemical analysis of MUC1 expression was conducted on a tissue microarray containing 278 human prostate sections obtained from 110 individuals. Of the 278 sections evaluated, 103 (37%) were nontumor tissue (ie, non-neoplastic) and 175 (63%) contained tumor tissue (Figure 2 ). Of those 278 sections, 42 (41%) of the nontumor sections and 30 (17%) of the tumor sections stained positively for MUC1, suggesting that there is a loss of MUC1 core protein expression in prostatic tumors when compared with non-neoplastic prostate tissue. Epithelia in sections of normal lung included in each array were uniformly positive for MUC1 with both antibodies used in these studies (data not shown). Since the staining patterns for both antibodies were similar in intensity and distribution in a given section, images obtained using only one of these antibodies (214D4) generally are shown for simplicity. Figure 4 panels a and b show a representative comparison of staining patterns obtained with the two antibodies. Non-neoplastic tissues consistently displayed an apical staining pattern. While no attempt was made to characterize the incidence of staining within each section, that is, the percentage of cells staining positively for MUC1, it was evident that there was considerable variability in the incidence, intensity, and the subcellular distribution both between and within sections ( Figure 3) . Some sections showed an apical expression pattern while other sections showed diffuse cytoplasmic staining or a mixture of both. Figure 4 illustrates the range of variability in MUC1 staining intensity and subcellular Figure 1 Western blot analysis of cell associated MUC1. PrEC, LNCaP, C4-2, C4-2B, PC-3, and DU-145 cells were cultured in the presence or absence of the cytokines IFN-g (50 ng/ml), TNF-a (100 ng/ml), and/or the androgen DHT (1 mM) as described in 'Materials and methods'. Following 24 h of serum starvation, cells were treated in serum-free medium for 24 h. Total cellular proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and evaluated for MUC1 protein levels using the 214D4 antibody as described in 'Materials and methods'. HES cell protein was included as a positive control and sample extraction buffer (SEB) was included as a background (negative) control. 
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distribution that was observed, and the threshold for positive staining (panel f). Prostate intraepithelial neoplasia (PIN), considered to be a neoplastic precursor to malignant progression, displayed the same variability as tumor tissue ( Figure 5 ). The proportion of MUC1-positive sections that fell into each of the three Gleason grades examined (Gleason grades 3-5) was similar to that observed with the MUC1-negative sections ( Table 2 ), indicating that there was no correlation between MUC1 expression and Gleason grade (MUC1-negative-52, 46, and 2% for Gleason grades 3, 4, and 5, respectively; MUC1-positive-63, 33, and 3% for Gleason grades 3, 4, and 5, respectively).
The Gleason grade for each positive tumor section also was correlated to the staining pattern in order to evaluate whether a loss of apical expression of MUC1 was associated with more progressive prostate cancers (Table 3) . Of the Gleason grade 3 sections, 1/18 (6%), 5/18 (28%), and 12/18 (67%) displayed apical, diffuse cytoplasmic, or mixed staining, respectively. Of the Gleason grade 4 sections, 0/9 (0%), 4/9 (44%), and 5/9 (56%) displayed apical, diffuse cytoplasmic, or mixed staining, respectively. There was only one Gleason grade 5 section and it displayed a diffuse cytoplasmic staining pattern. Overall, most tumor cells displayed a diffuse cytoplasmic staining pattern regardless of grade. While these results suggest that a loss of restriction of cell surface MUC1 to the apical cell membrane, reflecting reduced cellular polarization, no Gleason grades 1-2 sections were available to evaluate this hypothesis further. Moreover, it was not clear that there had been a redistribution of MUC1 at the cell surface in higher grade tumor cells, since in many tumor cells, no distinction could be made between cell membrane-associated and cytoplasmic MUC1. Overall, no correlation was observed between higher Gleason grade and the subcellular distribution of MUC1. 
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JC O'Connor et al Discussion MUC1 expression in cancer progression and metastasis is characterized by increased levels, altered glycosylation, and aberrant surface distribution patterns. 2, 4, [8] [9] [10] [11] [12] In particular, the extracellular domain of MUC1 facilitates cancer progression. It also can promote adhesion due to the presentation of carbohydrate ligands that bind to selectin-like molecules on endothelial cells. 27 Finally, the large size of the extracellular domain presents a formidable barrier to immune cells, thereby contributing to decreased immune response (reviewed in Gendler . These metastasis-promoting properties reside in the extracellular domain, and require cell surface expression to manifest. Intracellular MUC1 expression might still be able to alter cellular behavior by engaging signal transducing molecules via its cytoplasmic tail. [5] [6] [7] In this study, basal MUC1 protein expression was evaluated in normal prostate epithelial cells (PrEC) and a series of metastasis-derived prostate cancer cell lines, and was consistent with one previous report. 28 LNCaP cells and sublines, representing a model for progression to androgen independence and skeletal metastasis, 29 were negative for MUC1 expression, suggesting that the lack of MUC1 expression is a characteristic of LNCaP cells passed onto the sublines. It should be noted that genetic changes known to occur in LNCaP and sublines did not include the locus for MUC1. 30 Interestingly, Mitchell et al 28 reported that the benign immortalized prostatic cell lines PNT-1A, PNT-1B, and BPH-1 all had detectable MUC1 protein levels. However, since PrEC failed to express significant MUC1 under basal conditions, and two metastasis-derived lines did express MUC1, it appears that lack of MUC1 expression does not correlate strictly with malignancy. Of the five prostate cancer cell lines evaluated, DU-145 cells had the highest basal expression of MUC1. Our results with 
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PC-3 cells differ from that of Mitchell et al
28 who reported that unstimulated PC-3 cells were negative for MUC1 protein expression, whereas we found low basal MUC1 core protein expression in PC-3 cells. The most likely explanation for this discrepancy is that our use of MUC1 antibodies (214D4 and CT-1) not sensitive to glycoform variations, that is, more broadly recognizing MUC1, provides a more reliable method of revealing MUC1 protein expression.
In PrEC and PC-3 cells, MUC1 expression was elevated by cytokines. Androgen neither stimulated MUC1 directly nor potentiated MUC1 stimulation by cytokines in any cell line examined. Although this result was expected in androgen receptor-negative cell lines, the failure to see stimulation in the androgen-responsive LnCaP cell line may reflect an underlying defect in MUC1 expression since these cells also were unresponsive to cytokine stimulation. PrEC, in which androgen responsiveness may vary, uniformly responded to cytokine stimulation. Evangelou 33 In the aforementioned studies, 31, 33, 34 increased MUC1 expression was assessed in terms of its detection at the cell surface and thus could represent a redistribution to the surface of MUC1 already present in the cytoplasm and/or production of an altered MUC1 glycoform detectable by the antibodies utilized rather than an increase in MUC1 core protein. Indeed, in the only in vivo model of hormonal escape in which MUC1 expression has been examined (beside LNCaP), MUC1 expression in the androgen-dependent parental PAC120 xenograft was reported to be focally cytoplasmic and either focally cytoplasmic or membrane associated in the hormonally independent derivatives. 35 Interestingly, these studies demonstrated that MUC1 was not coexpressed by the cells expressing secreted mucins whose elevated expression correlated with hormonal escape. Taken together, these observations suggest that MUC1 expression and subcellular distribution may be very sensitive to the cellular context and partially explain the variability observed in prostate tissue sections.
Available reports on MUC1 expression in prostate and during prostate cancer progression are contradictory in key respects. For example, in normal prostate epithelia, MUC1 expression varied from strongly positive immunoreactivity 8 to weak or no immunoreactivity. 9, 12 Ho et al 8 reported intense staining in prostate adenocarcinomas (n ¼ 10). Zotter et al, 9 surveying several antibodies that produced weak or focally positive MUC1 staining in normal tissue, detected MUC1 in 9/10 tumors. However, they noted that a number of antibodies strongly positive on other tumors were weak on prostate cancers, indicating a difference in either the MUC1 glycoform itself or its relative abundance in prostate cancers. Utilizing antibody BC-1, recognizing hypoglycosylated MUC1, Ng et al 14 16 reported diffuse cytoplasmic and membrane staining even in low-grade tumors (Gleason 1-3 ). It is difficult to integrate this information into a cohesive picture of MUC1 expression during prostate cancer progression. While it seems that there is increased detectability of MUC1 associated with prostate cancer progression, it is not clear whether this reflects an increase in hypoglycosylated glycoforms, increased MUC1 core protein, or both. Two recent reports 15, 36 illustrated the variability in MUC1 detection in prostate with different antibodies whose ability to recognize their MUC1 protein core epitope is variously affected by the degree of MUC1 glycosylation. These factors further complicate interpretation of previous studies.
The availability of tissue arrays presented us with the opportunity to perform the largest single study yet undertaken to examine MUC1 core protein expression in benign and malignant human prostate tissue. Applying a combination of antibodies that would detect all forms of MUC1, 15, 37 we were able to detect MUC1 in only 41% of nontumor tissue (ie, benign), indicating that expression of MUC1 is variable in normal prostate. In contrast to studies utilizing antibodies recognizing hypoglycosylated forms of MUC1, our results demonstrated a reduction in MUC1 core protein expression in advanced prostate disease and no correlation with grade. These observations were confirmed in a gene profiling study recently published. 38 Positive MUC1 expression, although a strong predictor of tumor recurrence, was independent of tumor grade, and was present in only 26% of the 142 tumor tissues examined. Our data are consistent with that of Kirschenbaum et al 13 and Schut et al 15 in the sense that the expression pattern of MUC1 changed from apical to diffuse staining with more advanced prostate cancer, but it is not clear to what extent the MUC1 is cell membrane associated rather than cytoplasmic.
Another factor that may contribute to the variability in MUC1 expression in the prostate is the hormonal and cytokine mileau in patients from which the tissue samples are derived. As found for normal breast epithelia, breast cancer, and uterine cell lines, 18, 26, 39 we observed strong cytokine influences on MUC1 expression in normal prostate epithelia and certain prostate cancer cell lines (PC-3). In other prostate cancer cell lines, MUC1 either was constitutively expressed at high levels (DU-145) or not detected under any condition (LnCaP and derivative cell lines). In the latter case, we also failed to detect MUC1 expression in tumors formed when these cells were injected into the bone marrow of nude mice (JA Julian, DD Carson, and RA Sikes, unpublished results). Therefore, it is unlikely that our failure to detect MUC1 expression in these cells is due to a poor choice of cytokines as stimulants since bone marrow should provide a complex array of these factors and better mimic the environment of human bone metastases.
Overall, our data demonstrate that MUC1 expression is heterogeneous in both normal and malignant human prostate epithelia. Given its high degree of variable expression and sensitivity to environmental cues including steroid hormones and cytokines, we conclude that MUC1 expression is not likely to be a reliable indicator of prostate cancer grade or progression. Although altered MUC1 epitopes appear during the progression of prostate cancers, considering the incidence of MUC1 core protein expression in primary tumors, nonuniformity of MUC1 expression within tumors, and the reduction in membrane-associated MUC1 core protein observed in high-grade tumors, MUC1 also seems to be a poor choice as an immunotherapeutic target in prostate malignancies.
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